Digital Gene Technologies

Digital Gene Technologies, Inc. ("DGT"), deploys its TOGA®-based "Platform for Products" with strategic partners and more than 30 leading institutional researchers in support of molecular discovery, target and marker validation, and product development. DGT pursues its own proprietary franchises in cancer, diabetes and central nervous system pathol... ogies, such as schizophrenia, depression and Alzheimer's disease. Dramatically more sensitive, accurate and robust than array-based approaches, the open-system TOGA® methodology allows the cell or tissue finally to "speak for itself." The combination of the TOGA® robotic assay and integrated TOGA Portal informatics suite allows the researcher, at the desktop, to track and understand the development of disease, explore mechanisms of drug action, predict toxicity and profile patient populations. DGT's Integrative Biology teams provide follow-on expertise and support discovery and development programs from feasibility and exploratory studies to full technology transfer. A detailed description of DGT's TOGA® Method can be found in "TOGA: An automated parsing technology for analyzing expression of nearly all genes," J. Gregor Sutcliffe, et al, Proceedings of the National Academy of Sciences of the United States of America, volume 97, issue 5, pp. 1976-81 (2000) or at www.dgt.com.Read More